ALXN News and Press, Alexion Pharmaceuticals Inc. From 05/23/19

LOS ANGELES , May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico , Ph.D., initiates coverage on six stocks in the Healthcare and BioTech space. Initiations are on the following: Acer Therapeutics Inc. (ACER...

Achillion Pharmaceuticals (NASDAQ: ACHN ) is up  7%  premarket on light volume in response to preliminary data from a Phase 2 clinical trial evaluating factor D inhibitor ACH-4471 in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare inherited disorder characterized ...

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the RBC Capital Markets Annual Healthcare Conference in New York, NY on Tuesday, May 21, 2019 at 9:30 a.m. ET. An audio webcast of the presentation will be available live. You can access the webcast at...

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the UBS Global Healthcare Conference in New York, NY on Monday, May 20, 2019 at 11:30 a.m. ET. An audio webcast of the presentation will be available live. You can access the webcast at: http://ir.ale...

Catalyst Pharmaceuticals ( CPRX ) - As I'm writing this, the stock has lost 40% of its value in a single day after news came that the FDA approved Ruzurgi from Jacobus Pharma for LEMS (Lambert-Eaton myasthenic syndrome) patients age six to less than 17 years of age. This is the first app...

Read more ...

- New data published in NEJM confirm sustained three-year treatment effect - - Data will also be presented in Emerging Science session at American Academy of Neurology Annual Meeting - - SOLIRIS for NMOSD currently under regulatory review in the U.S., European Union and Japan; U.S...

Read more ...

Read more ...

Read more ...